Literature DB >> 24772346

Posterior reversible leukoencephalopathy syndrome secondary to hepatic transarterial chemoembolization with doxorubicin drug eluting beads.

C Andrew Kistler1, Joseph Caleb McCall1, Saad Sultan Ghumman1, Ijlal Akbar Ali1, Ali A Siddiqui1.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a rare complication of transarterial chemoembolization (TACE) used to treat liver metastases and has never been reported in a patient with metastatic uveal melanoma (UM) to the liver. We report the first case of PRES secondary to TACE with drug eluting beads (DEBs) loaded with doxorubicin in a 56-year-old woman with metastatic UM to the liver.

Entities:  

Keywords:  Posterior leukoencephalopathy; chemoembolization, therapeutic; doxorubicin; drug-eluting stents; syndrome

Year:  2014        PMID： 24772346      PMCID： PMC3999632          DOI： 10.3978/j.issn.2078-6891.2014.011

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  9 in total

1.  Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma.

Authors:  M J Edwards; R Walker; S Vinnicombe; C Barlow; P MacCallum; J M Foran
Journal:  Ann Oncol       Date:  2001-09       Impact factor: 32.976

Review 2.  Quality-improvement guidelines for hepatic transarterial chemoembolization.

Authors:  Antonio Basile; Gianpaolo Carrafiello; Anna Maria Ierardi; Dimitrios Tsetis; Elias Brountzos
Journal:  Cardiovasc Intervent Radiol       Date:  2012-05-31       Impact factor: 2.740

Review 3.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

4.  Unusual case of intra-arterial doxorubicin chemoembolization-associated posterior reversible encephalopathy syndrome.

Authors:  Pritish S Pawar; Ika Noviawaty; Osama O Zaidat
Journal:  Neurologist       Date:  2012-01       Impact factor: 1.398

Review 5.  Uveal melanoma: trends in incidence, treatment, and survival.

Authors:  Arun D Singh; Mary E Turell; Allan K Topham
Journal:  Ophthalmology       Date:  2011-06-24       Impact factor: 12.079

Review 6.  Metastatic uveal melanoma: biology and emerging treatments.

Authors:  Scott E Woodman
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

7.  Treatment of choroidal melanoma using photodynamic therapy.

Authors:  Irene A Barbazetto; Thomas C Lee; Indira S Rollins; Stanley Chang; David H Abramson
Journal:  Am J Ophthalmol       Date:  2003-06       Impact factor: 5.258

8.  Adverse events following transarterial chemoembolization for hepatocellular carcinoma and factors predicting such events.

Authors:  Abbas Ali Tasneem; Zaigham Abbas; Nasir Hassan Luck; Syed Mujahid Hassan; Syed Muhammad Faiq
Journal:  J Pak Med Assoc       Date:  2013-02       Impact factor: 0.781

9.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245
  9 in total
  2 in total

Review 1.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

2.  The first two cases of posterior reversible encephalopathy syndrome (PRES) secondary to conventional transcatheter arterial chemoembolization of hepatocellular carcinoma.

Authors:  Kefeng Jia; Weili Yin; Fang Wang; Zhongsong Gao; Cheng Sun; Hui Wang; Yujuan Han; Yongmei Wang; Mingge Li; Changlu Yu
Journal:  BMC Gastroenterol       Date:  2021-12-20       Impact factor: 3.067
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.